ArticleACS omega2026
Development of a Quantitative Serial LC-MS/MS Method for Gut Microbiota Metabolomics.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The significance of gut microbiota in human health has gained increasing attention. Accordingly, metabolomics has been used to elucidate host-microbiota interactions. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is an ideal choice for metabolome analysis of gut microbiota due to its quantitative capabilities. However, conventional LC-MS/MS requires multiple columns, multiple mobile phases, and complex procedures to optimize conditions for each target metabolite. To address these limitations, we developed a quantitative serial LC-MS/MS method, termed the Kobe University Serial LC-MS/MS Analysis using Multiple columns with a Single mobile phase (KUSLAMS). This platform integrates two columns (PFPP and C18) and a derivatization method for seamless, high-throughput quantification of 215 metabolites, including amino acids, nucleotides, carboxylic acids, amines, and fatty acids. Reproducibility for repeated analysis was assessed using 82 intracellular gut microbiota metabolites, for which new analytical methods were developed. Among these, 64 metabolites were detected with coefficients of variation (CV) below 15%. The application of KUSLAMS to an in vitro gut microbiota culture system with and without inulin revealed differences in the concentrations of 21 intracellular and 14 extracellular metabolites. Notably, several metabolites exhibited increased intracellular and decreased extracellular concentrations, suggesting a possible link between intracellular accumulation and extracellular depletion, although this interpretation is exploratory. These results indicate that KUSLAMS allows for the simultaneous monitoring of intra- and extracellular metabolite dynamics. Together, these findings demonstrate that KUSLAMS is a robust and versatile platform for the exploration of microbiota-derived metabolites relevant to human health.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.